Leerink Partners analyst Roanna Ruiz has maintained their bullish stance on LNTH stock, giving a Buy rating on July 23.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Roanna Ruiz has given her Buy rating due to a combination of factors that highlight Lantheus’ strong market position and future growth potential. Primarily, Lantheus is well-positioned in the PSMA PET imaging market with its product, Pylarify, which is a leader in this space. Additionally, the company’s strategic acquisitions in neurodiagnostics and oncology are expected to serve as significant growth drivers in the future.
Moreover, Ruiz believes that the current valuation of Lantheus is attractive, especially considering the recent decline in stock price following CMS reimbursement news. This presents a potential opportunity for investors, particularly if Lantheus’ upcoming earnings report exceeds expectations. Furthermore, the company’s management is anticipated to reaffirm their confidence in achieving double-digit revenue growth by 2026, which would positively impact the stock’s performance.
In another report released on July 23, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $81.00 price target.
LNTH’s price has also changed moderately for the past six months – from $92.530 to $72.200, which is a -21.97% drop .